All In Biotech

Drug Trial Radar · NCT03913143

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Last checked: Nov 19, 2026Latest source record: Mar 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

36

Actual

Start

Apr 4, 2019

Primary completion

Jan 31, 2022

Study completion Mar 2023

Sponsor

Lead sponsor
ProQR TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment

Conditions

  • Leber Congenital Amaurosis 10
  • Blindness
  • Leber Congenital Amaurosis
  • Vision Disorders
  • Sensation Disorders
  • Neurologic Manifestations
  • Eye Diseases
  • Eye Diseases, Hereditary
  • Eye Disorders Congenital
  • Retinal Disease

Interventions

  • sepofarsenDrug

    RNA antisense oligonucleotide for intravitreal injection

  • ShamOther

    Sham-Procedure (no experimental drug administered)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in BCVATime frame: 12 months

Locations

14 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Iowa

    Iowa City, Iowa

  • Universitair Ziekenhuis Gent (UZ)

    Ghent, Belgium

  • INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil

  • Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)

    São Paulo, São Paulo, Brazil

  • The Hospital for Sick Children - SickKids

    Toronto, Ontario, Canada

  • McGill University Health Centre - Centre for Innovative Medicine

    Montreal, Quebec, Canada

  • Centre de maladies rares CHNO des Quinze Vingt

    Paris, France

  • Hospital Civil de Strasbourg

    Strasbourg, France

  • Justus-Liebig Universität - Department of Ophthalmology

    Giessen, Germany

  • University of Tuebingen - Inst. for Ophthalmic Research

    Tübingen, Germany

  • Eye Clinic University of Campania Luigi Vanvitelli

    Naples, Italy

  • Amsterdam University Medica Center - Locatie AMC

    Amsterdam, Netherlands

  • Het Oogziekenhuis Rotterdam

    Rotterdam, Netherlands

  • Moorfields Eye Hospital - NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.